Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02D malaria vaccine in infants living in a malaria-endemic region

  • Salim Abdulla1, 9Email author,

    Affiliated with

    • Nahya Salim1,

      Affiliated with

      • Francisca Machera1,

        Affiliated with

        • Richard Kamata1,

          Affiliated with

          • Omar Juma1,

            Affiliated with

            • Mwanajaa Shomari1,

              Affiliated with

              • Sulende Kubhoja2,

                Affiliated with

                • Ali Mohammed1,

                  Affiliated with

                  • Grace Mwangoka1,

                    Affiliated with

                    • Thomas Aebi1, 3,

                      Affiliated with

                      • Hassan Mshinda4,

                        Affiliated with

                        • David Schellenberg5,

                          Affiliated with

                          • Terrell Carter6,

                            Affiliated with

                            • Tonya Villafana6,

                              Affiliated with

                              • Marie-Claude Dubois7,

                                Affiliated with

                                • Amanda Leach7,

                                  Affiliated with

                                  • Marc Lievens7,

                                    Affiliated with

                                    • Johan Vekemans7,

                                      Affiliated with

                                      • Joe Cohen7,

                                        Affiliated with

                                        • W Ripley Ballou7 and

                                          Affiliated with

                                          • Marcel Tanner3, 8

                                            Affiliated with

                                            Malaria Journal201312:11

                                            DOI: 10.1186/1475-2875-12-11

                                            Received: 7 August 2012

                                            Accepted: 4 January 2013

                                            Published: 8 January 2013

                                            Abstract

                                            Background

                                            The RTS,S/AS malaria candidate vaccine is being developed with the intent to be delivered, if approved, through the Expanded Programme on Immunization (EPI) of the World Health Organization. Safety, immunogenicity and efficacy of the RTS,S/AS02D vaccine candidate when integrated into a standard EPI schedule for infants have been reported over a nine-month surveillance period. This paper describes results following 20 months of follow up.

                                            Methods

                                            This Phase IIb, single-centre, randomized controlled trial enrolled 340 infants in Tanzania to receive three doses of RTS,S/AS02D or hepatitis B vaccine at 8, 12, and 16 weeks of age. All infants also received DTPw/Hib (diphtheria and tetanus toxoids, whole-cell pertussis vaccine, conjugated Haemophilus influenzae type b vaccine) at the same timepoints. The study was double-blinded to month 9 and single-blinded from months 9 to 20.

                                            Results

                                            From month 0 to 20, at least one SAE was reported in 57/170 infants who received RTS,S/AS02D (33.5%; 95% confidence interval [CI]: 26.5, 41.2) and 62/170 infants who received hepatitis B vaccine (36.5%; 95% CI: 29.2, 44.2). The SAE profile was similar in both vaccine groups; none were considered to be related to vaccination. At month 20, 18 months after completion of vaccination, 71.8% of recipients of RTS,S/AS02D and 3.8% of recipients of hepatitis B vaccine had seropositive titres for anti-CS antibodies; seroprotective levels of anti-HBs antibodies remained in 100% of recipients of RTS,S/AS02D and 97.7% recipients of hepatitis B vaccine. Anti-HBs antibody GMTs were higher in the RTS,S/AS02D group at all post-vaccination time points compared to control. According to protocol population, vaccine efficacy against multiple episodes of malaria disease was 50.7% (95% CI: -6.5 to 77.1, p = 0.072) and 26.7% (95% CI: -33.1 to 59.6, p = 0.307) over 12 and 18 months post vaccination, respectively. In the Intention to Treat population, over the 20-month follow up, vaccine efficacy against multiple episodes of malaria disease was 14.4% (95% CI: -41.9 to 48.4, p = 0.545).

                                            Conclusions

                                            The acceptable safety profile and good tolerability of RTS,S/AS02D in combination with EPI vaccines previously reported from month 0 to 9 was confirmed over a 20 month surveillance period in this infant population. Antibodies against both CS and HBsAg in the RTS,S/AS02D group remained significantly higher compared to control for the study duration. Over 18 months follow up, RTS,S/AS02D prevented approximately a quarter of malaria cases in the study population.

                                            Clinical trials

                                            Gov identifier: NCT00289185

                                            Keywords

                                            RTS,S/AS02 Falciparum Malaria Infants Immunogenicity Safety Efficacy EPI

                                            Background

                                            Globally, in 2010, an estimated 216 million people had malaria, 81% of which were from sub-Saharan Africa [1]. In 2010 in Africa, malaria resulted in approximately 596,000 deaths, 91% of which were in children under five years of age. Among the many approaches being pursued to control the disease, the development of safe and efficacious vaccines has been given high priority by national and international health authorities [2]. Used in conjunction with other control measures, a vaccine offers the possibility of accelerating and increasing the effectiveness of integrated malaria control.

                                            The RTS,S/AS candidate malaria vaccine is being developed for the routine immunization of infants and children living in malaria-endemic areas as part of the Expanded Programme of Immunization (EPI). The candidate vaccine has been evaluated with two different proprietary adjuvant systems, AS02 and AS01, both indicating an acceptable safety profile in children [310] and infants [1113] in clinical trials.

                                            A Phase IIb trial was conducted between July 2006 and February 2008 in Tanzania [12]. Infants aged 6 to 10 weeks at first vaccination received either RTS,S/AS02D or a hepatitis vaccine (Engerix-B™, GlaxoSmithKline [GSK]) as control. The RTS,S/AS02D candidate malaria vaccine consists of sequences of the circumsporozoite (CS) protein and hepatitis B surface antigen (HBsAg) with the adjuvant AS02D (proprietary oil-in-water emulsion formulated with MPL and QS21 immunostimulants). Both study vaccines were administered together with a vaccine containing diphtheria and tetanus toxoids, whole-cell pertussis vaccine, and conjugated Haemophilus influenzae type b vaccine (DTPw/Hib) (TETRActHib™, Aventis Pasteur).

                                            As reported previously, over a nine-month surveillance period, serious adverse events (SAEs) were reported in a similar proportion of subjects receiving the RTS,S/AS02D candidate vaccine (18.2%; 95% confidence interval [CI]: 12.7, 24.9) and hepatitis B vaccine (24.7%; 95% CI: 18.4, 31.9). Non-inferiority of the RTS,S/AS02D candidate vaccine in terms of antibody responses to EPI antigens was demonstrated. RTS,S/AS02D was shown to be highly immunogenic for anti-CS and -HBs antibodies. Using active detection of infection, efficacy of the RTS,S/AS02D candidate vaccine against first Plasmodium falciparum infection was 65.2% (95% CI: 20.7, 84.7; p = 0.01) over a 6 month period [12].

                                            This paper presents the 20 month follow up comparative data on the safety, immunogenicity and, as an exploratory endpoint, efficacy against malaria disease of RTS,S/AS02D in combination with EPI vaccines in the same population of infants aged six to 10 weeks at first vaccination.

                                            Methods

                                            Study design

                                            Details of study design, study vaccines and subject enrolment have been published elsewhere [12]. In brief, the study was a single centre, Phase IIb, randomized, controlled study conducted by the Bagamoyo Research and Training Centre, a branch of the Ifakara Health Institute (IHI; previously Ifakara Health Research and Development Centre-IHRDC) in Bagamoyo, Tanzania. The study was double-blind from months 0 to 9 and single-blind from months 9 to 20.

                                            The protocol was approved by the Ifakara Health Institute, the National Institute of Medical Research in Tanzania, Western Institutional Review Board in the United States, the Institutional Review Board of the London School of Hygiene and Tropical Medicine, and the Swiss Tropical and Public Health Institute (Swiss TPH, previously Swiss Tropical Institute; STI) through the local government ethics committee in Basel, Switzerland. The trial was undertaken in accordance with the provisions of the International Conference on Harmonization and Good Clinical Practice guidelines and was monitored by the sponsor, GSK Biologicals, which provided both the RTS,S/AS02D candidate vaccine and the hepatitis B vaccine.

                                            The design, conduct, and results of the trial were overseen by a formally constituted Independent Data Monitoring Committee (IDMC), operating under a charter. The IDMC included experts in malaria, paediatricians, and statisticians who were appointed to oversee the ethical and safety aspects of the study conduct. The role of the IDMC included review of the implementation and progress of the study. It provided initial, regular, and closing advice on safety-related issues to the sponsor. The trial aims and procedures were explained to participating communities and written informed consent in Swahili was obtained from each child’s parent(s) or guardian(s) before study procedures were initiated. Non-literate parents or guardians indicated consent using a thumbprint, and a signature was obtained from a literate witness.

                                            Malaria transmission in Bagamoyo area is perennial and almost entirely due to P. falciparum. Distribution of insecticide-treated bed nets is promoted through a National Malaria Control Programmes and artemether-lumefantrine (Coartem™) is currently the first-line treatment in Tanzania.

                                            Study subjects

                                            Eligibility criteria included any child born to a mother who was HBsAg negative, aged between six and 10 weeks at the time of first vaccination, who did not present with any serious acute or chronic illness as determined by clinical or physical examination, medical history records or laboratory screening tests of haematology, and renal and hepatic function.

                                            Randomization and vaccination

                                            Eligible subjects were randomized in a 1:1 ratio to receive three doses at 8, 12 and 16 weeks of age of either RTS,S/AS02D (25 μg of lyophilized RTS,S reconstituted with 500 μL of AS02D Adjuvant System) or three doses of hepatitis B vaccine (Engerix-B™; GlaxoSmithKline). All subjects received DTPw/Hib (TETRActHib™; Aventis Pasteur) at 8, 12 and 16 weeks of age.

                                            Surveillance of serious adverse events

                                            A morbidity surveillance system in place at Bagamoyo District Hospital (BDH) provided a comprehensive recording of all inpatient and outpatient attendances, investigational results, diagnosis and management. All parent(s)/guardian(s) of study children were educated on the appropriate action they should take if their child became unwell at any time during the study period; they were asked not to medicate their child at home, but to seek medical care at BDH. Sick children were provided transport to go to BDH.

                                            Study medical personnel

                                            Were available 24 hours per day at BDH to receive and identify study participants when they presented, and to ensure complete investigation and documentation of the attendance. At all other dispensaries in the study area, study medical personnel were available 24 hours a day to attend to patients and facilitate the transport of study participants to BDH.

                                            Evaluation of study subjects was according to IHI Standard Operating Procedures for the examination, investigation and documentation of each presentation. All information was recorded on an IHI clinic morbidity surveillance questionnaire. The questionnaires were subsequently reviewed by the Principal Investigator or delegate and any SAE identified as appropriate.

                                            Verbal autopsies were to be conducted on all children who died outside a health facility to ascribe the cause of death using a questionnaire adapted from the INDEPTH standard questionnaire [14].

                                            Immunogenicity assessment

                                            During the follow-up phase of the study, antibody titres for anti-CS and anti-HBs were assessed 12 months (Month 14) and 18 months (Month 20) after the third dose of vaccine. Antibody levels against CS were measured by standard ELISA methodology using plate-adsorbed R32LR antigen [NVDP(NANP)15 2LR [7] and expressed in ELISA Units/millilitre (EU/mL). Anti-HBs was measured using a GSK developed ELISA immunoassay, in mIU/mL. Both assays were performed at the laboratory of the Centre for Vaccinology (CEVAC), Ghent, Belgium.

                                            Monitoring for clinical malaria episodes

                                            Passive case monitoring (PCD) for malaria episodes was conducted at the health facilities within the study area throughout the study period. In addition, there was monitoring for the active detection of infection (ADI) every two weeks up to the detection of a first infection or up to study month 9. In summary, two weeks before administration of the third vaccine dose, asymptomatic parasitaemia was cleared with artemether–lumefantrine comprising six doses during a three-day period. Absence of parasitaemia after treatment was confirmed by blood analysis obtained two weeks later. Any subject who continued to have parasitaemia was retreated and the event excluded from the analysis. For ADI, blood samples were taken for examination of malaria parasitaemia at each visit. For PCD, any study subject presenting with fever (axillary temperature ≥37.5°C) within the preceding 24 hours underwent a blood draw for the determination of malaria parasites. Severe malaria was defined prospectively according to an agreed case definition and confirmed by medical review (Table 1).
                                            Table 1

                                            Severe malaria definitions for reporting of SAEs

                                            Severe malaria anaemia

                                            Asexual P. falciparum parasitemia > 0 definitive reading

                                             

                                            Haematocrit < 15%1

                                             

                                            No other more probable cause of illness

                                            Cerebral malaria

                                            Asexual P. falciparum parasitemia > 0 definitive reading

                                             

                                            Coma score ≤ 22

                                             

                                            No other identifiable cause of loss of consciousness

                                            Severe malaria (other)

                                            Asexual P. falciparum parasitemia > 0 definitive reading

                                             

                                            No other more probable cause of illness

                                             

                                            Does not meet criteria for severe malaria anaemia or cerebral malaria

                                             

                                            One of the following:

                                             

                                            Multiple seizures3

                                             

                                            Prostration4

                                             

                                            Hypoglycaemia5

                                             

                                            Acidosis

                                             

                                            Circulatory collapse

                                            Statistical analysis

                                            An analysis plan was prospectively agreed upon by the IDMC, sponsor and investigators. Statistical analyses were conducted using SAS version 8 (SAS, Cary, NC, USA). The primary study endpoint was of safety (occurrence of SAEs up to Month 20) with secondary endpoints of immunogenicity (anti-CS and anti-HBs antibody titres to Month 20). Additional endpoints for efficacy were also explored. All subjects who had received at least one dose of study vaccine were included in the safety analysis. The proportion of subjects with a SAE, classified by the Medical dictionary for regulatory activities (MedDRA) preferred term level [15], was tabulated with exact 95% CI. Episodes of severe malaria were tabulated with exact 95% Confidence Intervals (CI).

                                            The primary analysis for immunogenicity was performed on the According to Protocol (ATP) cohort, which included all evaluable subjects (i.e. those meeting all eligibility criteria, complying with the procedures defined in the protocol, with no elimination criteria during the study) and for whom data concerning immunogenicity endpoints were available. The percentage of subjects with seropositive levels of anti-CS antibodies (cut-off ≥ 0.5 EU/mL) and seroprotective levels of anti-HBs antibodies (cut-off ≥ 10 mIU/mL) with 95% CI were assessed. Antibody titres were summarized by geometric mean titres (GMT) with 95% CI for both antigens.

                                            The primary exploratory analysis for efficacy was performed on the ATP cohort, which included all enrolled subjects for whom data concerning efficacy endpoint measures were available, who received all 3 doses of study vaccine according to the randomization list, received clearance drug and were parasite negative at the start of the ADI period. The study evaluated efficacy against clinical malaria, according to primary and secondary case definitions (see Table 2). Time at risk started 14 days post dose 3 and was corrected for absences from the study area and anti-malarial drug use. Vaccine efficacy (VE) against first or only episodes of clinical malaria was assessed using Cox regression models, defined as 1-R where R is the hazard ratio of the RTS,S/AS02D group against control (with 95% CI). Schoenfeld p-values and models with time varying covariates were evaluated to check proportionality of hazards. VE against multiple episodes was calculated using Poisson regression with random effects defined as 1- incident rate ratio. For the ATP analyses, VE estimates were adjusted for village of residence and distance to BDH.
                                            Table 2

                                            Case definitions for clinical malaria

                                            Primary Case Definition

                                            · The presence of P. falciparum asexual parasitaemia above 500 per μL) on Giemsa stained thick blood films AND

                                             

                                            · the presence of fever (axillary temperature ≥ 37.5°C)

                                            Secondary Case Definition

                                            · The presence of P. falciparum asexual parasitaemia above 0 per μL) on Giemsa stained thick blood films AND

                                             

                                            · the presence of fever (axillary temperature ≥ 37.5°C) or history of fever in the previous 24 hours

                                            Results

                                            Subject cohort

                                            A total of 340 infants were randomly assigned to a study group and received at least one vaccination (Total Vaccinated Cohort: 170 RTS,S/AS02D, 170 hepatitis B vaccine). Figure 1 summarizes subject participation during the course of the study. The month 20 visit was completed by 144 subjects in the RTS,S/AS02D group and 142 subjects in the hepatitis B vaccine group. From month 0 to 20, 54 subjects withdrew from the study, 26 from the RTS,S/AS02D group and 28 from the hepatitis B group. The main reason for withdrawal in both groups was migration out of the study area.
                                            http://static-content.springer.com/image/art%3A10.1186%2F1475-2875-12-11/MediaObjects/12936_2012_2629_Fig1_HTML.jpg
                                            Figure 1

                                            CONSORT diagram for study participants. a Subjects were temporarily out of study area but returned for the Month 14 visit. b Other: investigator decided not to continue vaccination as EPI vaccination documentation was not available, this subject returned for the Month 14 visit. c One subject died after consent withdrawal; death was not considered related to vaccination.

                                            The basic parameters of those withdrawing were not different compared to the remaining study population. The demographic profile of subjects in the RTS,S/AS02D and hepatitis B vaccine groups was balanced in terms of age and gender. At the time of first vaccine administration the mean age of subjects was 7.8 (SD 0.77) weeks and 7.9 (SD 0.83) weeks in the RTS,S/AS02D and hepatitis B vaccine groups, respectively. A similar proportion of subjects were males in both the RTS,S/AS02D and hepatitis B vaccine groups (47% and 50%, respectively).

                                            Safety outcomes

                                            From the time of first vaccination until Month 20, 57 (33.5%) recipients of RTS,S/AS02D and 62 (36.5%) recipients of hepatitis B vaccine, in co-administration with DTPw/Hib, reported at least one SAE (Table 3). No SAE was considered by the investigator to be related to vaccine. There were no concerning imbalances in the cause of SAEs.
                                            Table 3

                                            SAEs occurring in more than one subject classified by MedDRA preferred term (Total Vaccinated Cohort [Months 0–20])

                                             

                                            Hepatitis B vaccine N = 170

                                            RTS,S/AS02DN = 170

                                            Preferred Term

                                            n

                                            %

                                            95% CI

                                             

                                            n

                                            %

                                            95% CI

                                             

                                            At least one SAE

                                            62

                                            36.5

                                            29.2

                                            44.2

                                            57

                                            33.5

                                            26.5

                                            41.2

                                            Pneumonia

                                            36

                                            21.2

                                            15.3

                                            28.1

                                            25

                                            14.7

                                            9.7

                                            20.9

                                            P. falciparum infection

                                            25

                                            14.7

                                            9.7

                                            20.9

                                            19

                                            11.2

                                            6.9

                                            16.9

                                            Anaemia

                                            16

                                            9.4

                                            5.5

                                            14.8

                                            16

                                            9.4

                                            5.5

                                            14.8

                                            Gastroenteritis

                                            12

                                            7.1

                                            3.7

                                            12.0

                                            16

                                            9.4

                                            5.5

                                            14.8

                                            Febrile convulsion

                                            2

                                            1.2

                                            0.1

                                            4.2

                                            5

                                            2.9

                                            1.0

                                            6.7

                                            Urinary tract infection

                                            3

                                            1.8

                                            0.4

                                            5.1

                                            4

                                            2.4

                                            0.6

                                            5.9

                                            Lymphadenitis

                                            0

                                            0.0

                                            0.0

                                            2.1

                                            3

                                            1.8

                                            0.4

                                            5.1

                                            Abscess

                                            2

                                            1.2

                                            0.1

                                            4.2

                                            2

                                            1.2

                                            0.1

                                            4.2

                                            Bronchiolitis

                                            1

                                            0.6

                                            0.0

                                            3.2

                                            2

                                            1.2

                                            0.1

                                            4.2

                                            Sepsis

                                            2

                                            1.2

                                            0.1

                                            4.2

                                            2

                                            1.2

                                            0.1

                                            4.2

                                            Upper respiratory tract infection

                                            3

                                            1.8

                                            0.4

                                            5.1

                                            2

                                            1.2

                                            0.1

                                            4.2

                                            Convulsion

                                            2

                                            1.2

                                            0.1

                                            4.2

                                            2

                                            1.2

                                            0.1

                                            4.2

                                            Acarodermatitis

                                            2

                                            1.2

                                            0.1

                                            4.2

                                            0

                                            0.0

                                            0.0

                                            2.1

                                            Bronchial hyperreactivity

                                            3

                                            1.8

                                            0.4

                                            5.1

                                            0

                                            0.0

                                            0.0

                                            2.1

                                            At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term).

                                            N = number of subjects with at least one administered dose.

                                            n/% = number/percentage of subjects reporting at least once the symptom.

                                            95% CI = exact 95% confidence interval.

                                            Two SAEs were fatal, one occurring during the double-blind phase (severe pneumonia/symptomatic seizure) in a subject from the hepatitis B vaccine group and one during the single-blind phase of the study (cerebral malaria) in a subject from the RTS,S/AS02D group. On analysis of predefined cases of severe malaria, five subjects in the RTS,S/AS02D group and four subjects in the hepatitis B vaccine group were reported as having severe malaria. Apart from the fatal SAEs, no subject was withdrawn from the study due to an adverse event.

                                            Immunogenicity outcomes

                                            Anti-CS response

                                            Pre-vaccination, a similar proportion of subjects was seropositive for anti-CS antibodies in the RTS,S/AS02D and hepatitis B vaccine, co-administered with DTPw/Hib, groups (23.4% and 25.7%, respectively) (Table 4). The pre-vaccination anti-CS antibody GMTs were below the assay cut-off (<0.5 EU/mL) in both groups.
                                            Table 4

                                            Seropositivity rates and GMTs for anti-CS antibodies from Months 0 to 20 (ATP Cohort for Immunogenicity)

                                            Group

                                            Timing

                                            N

                                            Seropositive

                                            GMT (EU/mL)

                                              
                                               

                                            n

                                            %

                                            95% CI

                                             

                                            value

                                            95% CI

                                             

                                            RTS,S/AS02D

                                            SCREENING

                                            141

                                            33

                                            23.4

                                            16.7

                                            31.3

                                            0.3

                                            0.3

                                            0.4

                                             

                                            Post Dose 2 (Month 2)

                                            151

                                            149

                                            98.7

                                            95.3

                                            99.8

                                            28.9

                                            22.4

                                            37.3

                                             

                                            Post Dose 3 (Month 3)

                                            143

                                            141

                                            98.6

                                            95.0

                                            99.8

                                            69.5

                                            53.9

                                            89.6

                                             

                                            Post Dose 3 (Month 9)

                                            143

                                            127

                                            88.8

                                            82.5

                                            93.5

                                            6.2

                                            4.6

                                            8.3

                                             

                                            Post Dose 3 (Month 14)

                                            142

                                            107

                                            75.4

                                            67.4

                                            82.2

                                            3.0

                                            2.2

                                            4.0

                                             

                                            Post Dose 3 (Month 20)

                                            131

                                            94

                                            71.8

                                            63.2

                                            79.3

                                            1.9

                                            1.4

                                            2.6

                                            Hepatitis B

                                            SCREENING

                                            152

                                            39

                                            25.7

                                            18.9

                                            33.4

                                            0.4

                                            0.3

                                            0.4

                                            vaccine

                                            Post Dose 2 (Month 2)

                                            156

                                            10

                                            6.4

                                            3.1

                                            11.5

                                            0.3

                                            0.3

                                            0.3

                                             

                                            Post Dose 3 (Month 3)

                                            144

                                            2

                                            1.4

                                            0.2

                                            4.9

                                            0.3

                                            0.2

                                            0.3

                                             

                                            Post Dose 3 (Month 9)

                                            147

                                            0

                                            0.0

                                            0.0

                                            2.5

                                            0.3

                                            0.3

                                            0.3

                                             

                                            Post Dose 3 (Month 14)

                                            139

                                            2

                                            1.4

                                            0.2

                                            5.1

                                            0.3

                                            0.2

                                            0.3

                                             

                                            Post Dose 3 (Month 20)

                                            132

                                            5

                                            3.8

                                            1.2

                                            8.6

                                            0.3

                                            0.3

                                            0.3

                                            Seropositive ≥ 0.5 EU/mL.

                                            N = number of subjects with available results.

                                            n/% = number/percentage of subjects with titre within the specified range.

                                            At month 14 and month 20, 75.4% and 71.8% of subjects in the RTS,S/AS02D group were seropositive for anti-CS antibodies, compared to 1.4% and 3.8% of subjects in the hepatitis B vaccine group. At month 14, anti-CS antibody GMTs in the RTS,S/AS02D were low (3.0 EU/mL) which decreased further at month 20 (1.9 EU/mL), but were still higher than the hepatitis B control group (<0.5 EU/mL).

                                            Anti-HBs response

                                            Subjects enrolled in this study were born to HBsAg-negative mothers and no neonatal Hepatitis B immunization programme was in place. Thus, the subjects had received no previous Hepatitis B vaccine. Prior to vaccination, the proportion of subjects with seroprotective levels of maternal anti-HBs antibodies derived from passive transfer during pregnancy was similar in the RTS,S/AS02D and hepatitis B vaccine, co-administered with DTPw/Hib, groups (38.3% and 34.4%, respectively) (Table 5). On average, pre-vaccination anti-HBs antibody GMTs were low (<15 mIU/mL).
                                            Table 5

                                            Seroprotective rates and GMTs for anti-HBs antibodies from Months 0 to 20 (ATP Cohort for Immunogenicity)

                                            Group

                                            Timing

                                            N

                                            Seroprotected

                                            GMT (mIU/mL)

                                               

                                            n

                                            %

                                            95% CI

                                             

                                            Value

                                            95% CI

                                             

                                            RTS,S/AS02D

                                            SCREENING

                                            115

                                            44

                                            38.3

                                            29.4

                                            47.8

                                            14.5

                                            10.9

                                            19.2

                                             

                                            Post Dose 2 (Month 2)

                                            148

                                            140

                                            94.6

                                            89.6

                                            97.6

                                            110.9

                                            89.1

                                            138.1

                                             

                                            Post Dose 3 (Month 3)

                                            140

                                            140

                                            100

                                            97.4

                                            100

                                            667.3

                                            532.9

                                            835.7

                                             

                                            Post Dose 3 (Month 20)

                                            131

                                            131

                                            100

                                            97.2

                                            100

                                            1520.6

                                            1206.8

                                            1915.8

                                            Hepatitis B

                                            SCREENING

                                            131

                                            45

                                            34.4

                                            26.3

                                            43.1

                                            13.3

                                            10.0

                                            17.6

                                            vaccine

                                            Post Dose 2 (Month 2)

                                            147

                                            82

                                            55.8

                                            47.4

                                            64.0

                                            17.1

                                            13.6

                                            21.4

                                             

                                            Post Dose 3 (Month 3)

                                            141

                                            133

                                            94.3

                                            89.1

                                            97.5

                                            113.8

                                            91.3

                                            141.8

                                             

                                            Post Dose 3 (Month 20)

                                            132

                                            129

                                            97.7

                                            93.5

                                            99.5

                                            184.3

                                            144.4

                                            235.4

                                            Seroprotected ≥ 10 mIU/mL.

                                            N = number of subjects with available results.

                                            n/% = number/percentage of subjects with titre within the specified range.

                                            Seroprotective levels of anti-HBs antibodies at month 20 were achieved in 100% of recipients of RTS,S/AS02D co-administered with DTPw/Hib and 97.7% of recipients of hepatitis B vaccine co-administered with DTPw/Hib. The anti-HBs antibody GMT at Month 20 was greater in recipients of RTS,S/AS02D (1521 mIU/mL) than in recipients of hepatitis B vaccine (184 mIU/mL).

                                            Efficacy outcomes

                                            Over 12-month and 18-month periods following Dose 3 of study vaccine, VE of RTS,S/AS02D against the primary case definition for multiple episodes of disease was 50.7% (p = 0.072) and 26.7% (p = 0.307), respectively, and for first or only episode of clinical malaria 53.6% (p = 0.026) and 34.9% (p = 0.101), respectively (Table 6). Figure 2 shows Kaplan–Meier curves of the cumulative incidence of first or only malaria episodes in the two study groups (Primary Case Definition). In the intention to treat (ITT) population vaccine efficacy against all episodes of malaria over the entire follow up starting at dose 1 was 14.4% (95% CI: -41.9 to 48.4, p = 0.545).
                                            Table 6

                                            Vaccine efficacy against P. falciparum disease (ATP Cohort for Efficacy)

                                            RTS,S/AS02D

                                            Hepatitis B Vaccine

                                            Point estimate of VE adjusted for covariates

                                            Subjects (N)

                                            No. of events

                                            PYAR

                                            Subjects (N)

                                            No. of events

                                            PYAR

                                            (%)

                                            95% CI

                                             

                                            P value

                                            Primary Case Definition: multiple episodes

                                            Months 2.5 – 14

                                            146

                                            18

                                            124.48

                                            151

                                            30

                                            127.91

                                            50.7

                                            −6.5

                                            77.1

                                            0.072

                                            Months 2.5 – 20

                                            146

                                            42

                                            193.41

                                            151

                                            51

                                            198.29

                                            26.7

                                            −33.1

                                            59.6

                                            0.307

                                            Primary Case Definition: first or only

                                            Months 2.5 – 14

                                            146

                                            13

                                            121.04

                                            151

                                            24

                                            121.34

                                            53.6

                                            8.6

                                            76.4

                                            0.026

                                            Months 2.5 – 20

                                            146

                                            26

                                            181.92

                                            151

                                            34

                                            178.56

                                            34.9

                                            −8.8

                                            61.1

                                            0.101

                                            PYAR: Episodes/Person Years at Risk; VE: Vaccine Efficacy (1-HR); CI: Confidence Interval; p value from Cox PH model; Poisson regression for multiple episodes.

                                            http://static-content.springer.com/image/art%3A10.1186%2F1475-2875-12-11/MediaObjects/12936_2012_2629_Fig2_HTML.jpg
                                            Figure 2

                                            Kaplan-Meier survival curves showing the cumulative incidence of P. falciparum disease, Primary Case Definition (ATP Cohort for Efficacy [Months 2.5 - 20]). Eng = Engerix-B Hepatitis B vaccine.

                                            Over the same time periods, respectively, VE of RTS,S/AS02D against the Secondary Case Definition for multiple episodes of disease was 53.5% (95% CI: 3.3, 77.6; p = 0.040) and 26.2% (95% CI: -19.0, 54.2; p = 0.212) and for first or only episode of clinical malaria was 55.7% (95% CI: 15.4, 76.8; p = 0.014) and 32.0% (95% CI: -6.4, 56.5; p = 0.091). A test based on the Schoenfeld residuals (p = 0.1919) suggested no violation of the proportional hazards assumption over the follow up period, consistent with a constant effect over the course of the study.

                                            Discussion

                                            This paper further contributes key information on the safety, immunogenicity and efficacy profile over a 20 month follow up period of the candidate malaria RTS,S adjuvanted vaccine when co-administered to infants alongside routine immunizations included in the Expanded Programme of Immunization.

                                            This study shows that, over 12 and 18 months of follow up post vaccination: vaccine efficacy against multiple episodes of malaria disease was 50.7% and 26.7%, respectively, in the ATP population. Vaccine efficacy against multiple episodes of malaria disease in the ITT population, starting at first dose of vaccine, was lower (14%). Including ITT analysis provides fair comparisons among the vaccinated population, but perfect adherence to the protocol, especially for phase II studies, is crucial. Results from ATP analyses aim to predict the true biological efficacy of the vaccine.

                                            Initial results demonstrated that RTS,S/AS02D has an acceptable safety profile, that it can be given in co-administration with EPI vaccines and provides protection against first P. falciparum infection of approximately 65% (p = 0.01) over 6 months of follow up [12].

                                            As an exploratory endpoint in this follow up study, vaccine efficacy against multiple episodes of clinical disease was 51%, though not achieving statistical significance (p = 0.072), and 54% against first or only episode of clinical disease (p = 0.026), over 12 months post-vaccination. These results are consistent with those of a trial evaluating safety, immunogenicity and efficacy of RTS,S/AS01 in co-administration with EPI vaccines in infants [13]. Similar levels of protection have been observed in children 5–17 months old upon first RTS,S/AS01 vaccination in a Phase II trial conducted in Tanzania and Kenya [16].

                                            However, the large multi-country, multi-site RTS,S/AS01 Phase III trial showed that in young infants the vaccine provided modest protection against malaria when co-administered with EPI vaccines [17]. The fact that most of the participants in the Phase III study come from high transmission areas indicates that RTS,S protection may be influenced by other factors including level of transmission.

                                            While CIs are wide, and models, including time-varying covariates and Schoenfeld residuals (p = 0.192), do not support waning in vaccine efficacy, a longer follow-up of infants post-vaccination showed lower levels of protection in this trial (27% over 18 months), which was not significant at the 5% level (p = 0.307). This is in contrast with a study with the RTS,S/AS01 formulation in infants, which showed protection of 59% over 19 months of follow up (p < 0.001) [18].

                                            The reduction in the level of protection observed after 18 months, when compared to the level observed at 12 months, was also reported in a study with 45 months of follow up [19]. While it is not impossible that the close follow up during the ADI period may have impacted VE estimates in this trial, a possible explanation could be due to a combination of (i) true decay in vaccine-induced protection over the period of follow up, (ii) the decline in the number of susceptible subjects due to rapid acquisition of immunity, and/or (iii) variability in malaria transmission and exposure. Similar observations were made in recent long-term follow-up studies of RTS,S/AS02 [6, 7, 912, 20, 21].

                                            The assessment of anti-CS antibody titres shows that at 18 months post vaccination 71.8% of RTS,S/AS02 recipients remain seropositive. While remaining higher than those seen in the control group, antibody levels are much lower than early after vaccination. Although no protective threshold has been established, anti-CS antibody levels have been shown to be associated with protection [18, 22, 23]. The relatively low immune responses of RTS,S/AS02 to anti-CS observed in this trial, compared to the AS01E formulation, may have also contributed to the apparent drop in long-term protection.

                                            As seen in other studies of RTS,S/AS02 and RTS,S/AS01 [313, 22, 23], post vaccination anti-HBs seroprotection rates and GMTs are high. In this study, at month 20 they remained greater than in recipients of hepatitis B vaccine. This supports the fact that the RTS,S candidate vaccine also confers protection against Hepatitis B virus (HBV).

                                            The observation of an acceptable safety profile of RTS,S/ASO2D over 20 months of follow up is consistent with long term safety follow up of RTS,S/AS01 in infants [13]. No safety concerns appeared upon SAE review over the duration of follow up. Few children died and severe malaria rates were lower than expected in this setting, which may be due to close follow up of this cohort. Clinically diagnosed pneumonia, reported as SAEs and classified by MedDRA preferred terms [15], tended to be more frequently reported among hospitalized participants in the hepatitis B vaccine group at 9 months post vaccination [12], and this effect was less marked in the current data set to 20 months. A tendency for pneumonia rates to be lower may be due to a variety of reasons, including chance findings, lack of accurate diagnosis for pneumonia and/or the possibility that the malaria candidate vaccine reduced the indirect consequences of malaria. A more rigorous assessment of the co-morbidities is ongoing in the Phase III trial [17, 22].

                                            The acceptable vaccine safety profile and the efficacy data obtained in this trial in the context of co-administration of EPI vaccines adds to the growing body of evidence that, if approved, the RTS,S candidate vaccine could contribute to the reduction of the malaria disease burden in infants and children and become an additional component of integrated malaria control strategies.

                                            Trademarks

                                            Coartem™ is a registered trademark of Novartis Pharma AG.

                                            Engerix™ is a registered trademark of GlaxoSmithKline.

                                            TETRActHib™ is a registered trademark of Aventis Pasteur.

                                            GSK Study ID number: 104298 (Malaria-040).

                                            Declarations

                                            Acknowledgements

                                            The trial was supported by the PATH Malaria Vaccine Initiative (MVI) and by GSK Biologicals. We thank all the children and parents who participated in this study; the Bagamoyo communities and their leaders; the entire staff at Bagamoyo Research and Training Centre of Ifakara Health Institute, Bagamoyo District Hospital, and the dispensaries in the study area; and Zaria Said and Richard Kamata, study counselors. The staff at the Swiss TPH, Basel, for providing key support to this trial and acting as site partners; Christoph Hatz for serving as a liaison between the trial team and the Swiss institutional review boards; Christine Walliser and Christian Wirz for their administrative and logistic support; Hans-Peter Marti for providing assistance with laboratory procedures; Rahiya Shariff for her coordination of the communications team; our colleagues in other trial sites supported by MVI through the Bill and Melinda Gates Foundation, particularly the team from Centro de Investigacao em Saude de Manhica at Manhica, Mozambique, which provided support and advice for the implementation of the trial; the staff of the Malaria Project Team at GSK Biologicals, particularly Nathalie Annez, Delphine Beauport, Sarah Benns, Issam Jaimai, Isabelle Ramboer, Shantala Rao, Christine Swysen, Marie Chantal Uwamwezi, and Laurence Vigneron. We are grateful to the fruitful exchanges with our colleagues in the various other MVI supported trial sites through the CPTC network and the MCTA initiative of the Bill & Melinda Gates Foundation, particularly the team of Manhica that provided support and advice for building up BRTC-IHI and the implementation of the trial based on their experience with the proof-of concept trial and the staggered approach among infants. Christian Loucq, Melinda Moree, and Regina Rabinovich for their hard work and dedication to the project; Karim Manji for providing continuous support and guidance; Malcolm Molyneux, chair of the data and safety monitoring board, for his instruction and support; Andrew Kitua, director of the National Institute of Health at the Ministry of Health and Social Welfare; and the staff of the Contract Laboratory Services of South Africa for providing invaluable support.

                                            Funding

                                            The study was sponsored by GSK Biologicals SA Belgium, the vaccine developer and manufacturer, and funded by the PATH Malaria Vaccine Initiative.

                                            Authors’ Affiliations

                                            (1)
                                            Bagamoyo Research and Training Centre of Ifakara Health Institute
                                            (2)
                                            Muhimbili University of Health and Allied Sciences
                                            (3)
                                            Swiss Tropical and Public Health Institute
                                            (4)
                                            Tanzania Commission for Science and Technology
                                            (5)
                                            London School of Hygiene and Tropical Medicine
                                            (6)
                                            PATH Malaria Vaccine Initiative
                                            (7)
                                            GlaxoSmithKline Biologicals
                                            (8)
                                            University of Basel
                                            (9)
                                            Ifakara Health Institute

                                            References

                                            1. WHO: World malaria report 2010. Geneva: World Health Organization; 2010.
                                            2. WHO/IVR: [http://​www.​who.​int/​vaccine_​research/​links/​Rainbow/​en/​index.​html] Initiative for vaccine research: World Health Organization. 2011.
                                            3. Bojang KA, Olodude F, Pinder M, Ofori-Anyinam O, Vigneron L, Fitzpatrick S, Njie F, Kassanga A, Leach A, Milman J, Rabinovich R, McAdam KP, Kester KE, Heppner DG, Cohen JD, Tornieporth N, Milligan PJ: Safety and immunogenicty of RTS, S/AS02A candidate malaria vaccine in Gambian children. Vaccine 2005, 23:4148–4157.PubMedView Article
                                            4. Macete E, Aponte JJ, Guinovart C, Sacarlal J, Ofori-Anyinam O, Mandomando I, Espasa M, Bevilacqua C, Leach A, Dubois MC, Heppner DG, Tello L, Milman J, Cohen J, Dubovsky F, Tornieporth N, Thompson R, Alonso PL: Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1–4 in Mozambique. Trop Med Int Health 2007, 12:37–46.PubMed
                                            5. Sacarlal J, Aponte JJ, Aide P, Mandomando I, Bassat Q, Guinovart C, Leach A, Milman J, Macete E, Espasa M, Ofori-Anyinam O, Thonnard J, Corachan S, Dubois MC, Lievens M, Dubovsky F, Ballou WR, Cohen J, Alonso PL: Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial. Vaccine 2008, 26:174–184.PubMedView Article
                                            6. Sacarlal J, Aide P, Aponte JJ, Renom M, Leach A, Mandomando I, Lievens M, Bassat Q, Lafuente S, Macete E, Vekemans J, Guinovart C, Sigauque B, Sillman M, Milman J, Dubois MC, Demoitie MA, Thonnard J, Menendez C, Ballou WR, Cohen J, Alonso PL: Long-term safety and efficacy of the RTS, S/AS02A malaria vaccine in Mozambican children. J Infect Dis 2009, 200:329–336.PubMedView Article
                                            7. Macete EV, Sacarlal J, Aponte JJ, Leach A, Navia MM, Milman J, Guinovart C, Mandomando I, Lopez-Pua Y, Lievens M, Owusu-Ofori A, Dubois MC, Cahill CP, Koutsoukos M, Sillman M, Thompson R, Dubovsky F, Ballou WR, Cohen J, Alonso PL: Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial. Trials 2007,8(11):1745–6215.
                                            8. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Mshamu S, Lang T, Gould J, Dubois MC, Demoitie MA, Stallaert JF, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Ballou WR, Cohen J, Riley EM, Lemnge MM, Marsh K, Von SL: Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008, 359:2521–2532.PubMedView Article
                                            9. Lell B, Agnandji S, von Glasenapp I, Haertle S, Oyakhiromen S, Issifou S, Vekemans J, Leach A, Lievens M, Dubois MC, Demoitie MA, Carter T, Villafana T, Ballou WR, Cohen J, Kremsner PG: A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS One 2009, 4:e7611.PubMedView Article
                                            10. Owusu-Agyei S, Ansong D, Asante K, Kwarteng OS, Owusu R, Wireko Brobby NA, Dosoo D, Osei AA, Osei-Kwakye K, Adjei EA, Boahen KO, Sylverken J, Adjei G, Sambian D, Apanga S, Kayan K, Vekemans J, Ofori-Anyinam O, Leach A, Lievens M, Demoitie MA, Dubois MC, Cohen J, Ballou WR, Savarese B, Chandramohan D, Gyapong JO, Milligan P, Antwi S, Agbenyega T, Greenwood B, Evans J: Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS One 2009, 4:e7302.PubMedView Article
                                            11. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, Sacarlal J, Manaca MN, Lafuente S, Barbosa A, Leach A, Lievens M, Vekemans J, Sigauque B, Dubois MC, Demoitie MA, Sillman M, Savarese B, McNeil JG, Macete E, Ballou WR, Cohen J, Alonso PL: Safety of the RTS, S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 2007, 370:1543–1551.PubMedView Article
                                            12. Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, Membi C, Omari S, Urassa A, Mshinda H, Jumanne A, Salim N, Shomari M, Aebi T, Schellenberg DM, Carter T, Villafana T, Demoitie MA, Dubois MC, Leach A, Lievens M, Vekemans J, Cohen J, Ballou WR, Tanner M: Safety and immunogenicity of RTS, S/AS02D malaria vaccine in infants. N Engl J Med 2008, 359:2533–2544.PubMedView Article
                                            13. Agnandji ST, Asante KP, Lyimo J, Vekemans J, Soulanoudjingar SS, Owusu R, Shomari M, Leach A, Fernandes J, Dosoo D, Chikawe M, Issifou S, Osei-Kwakye K, Lievens M, Paricek M, Apanga S, Mwangoka G, Okissi B, Kwara E, Minja R, Lange J, Boahen O, Kayan K, Adjei G, Chandramohan D, Jongert E, Demoitie MA, Dubois MC, Carter T, Vansadia P, Villafana T, Sillman M, Savarese B, Lapierre D, Ballou WR, Greenwood B, Tanner M, Cohen J, Kremsner PG, Lell B, Owusu-Agyei S, Abdulla S: Evaluation of the safety and immunogenicity of the RTS, S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis 2010, 202:1076–1087.PubMedView Article
                                            14. WHO: [http://​who.​int/​healthinfo/​statistics/​verbalautopsysta​ndards/​en/​] Verbal Autopsy Standards: ascertaining and attributing cause of death. 2007.
                                            15. MedDRA: [http://​www.​ich.​org/​products/​meddra.​html] The medical dictionary for regulatory activities. 2007.
                                            16. Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, Lang T, Gould J, Dubois MC, Jongert E, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Lapierre D, Ballou WR, Cohen J, Lemnge MM, Peshu N, Marsh K, Riley EM, Von SL, Bejon P: Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis 2011, 11:102–109.PubMedView Article
                                            17. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Mordmuller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Machevo S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, Abdulla S, Salim N, Minja R, Mpina M, Ahmed S, Ali AM, Mtoro AT, Hamad AS, Mutani P, Tanner M, Tinto H, D’Alessandro U, Sorgho H, Valea I, Bihoun B, Guiraud I, Kabore B, Sombie O, Guiguemde RT, Ouedraogo JB, Hamel MJ, Kariuki S, Oneko M, Odero C, Otieno K, Awino N, McMorrow M, Muturi-Kioi V, Laserson KF, Slutsker L, Otieno W, Otieno L, Otsyula N, Gondi S, Otieno A, Owira V, Oguk E, Odongo G, Woods JB, Ogutu B, Njuguna P, Chilengi R, Akoo P, Kerubo C, Maingi C, Lang T, Olotu A, Bejon P, Marsh K, Mwambingu G, Owusu-Agyei S, Asante KP, Osei-Kwakye K, Boahen O, Dosoo D, Asante I, Adjei G, Kwara E, Chandramohan D, Greenwood B, Lusingu J, Gesase S, Malabeja A, Abdul O, Mahende C, Liheluka E, Malle L, Lemnge M, Theander TG, Drakeley C, Ansong D, Agbenyega T, Adjei S, Boateng HO, Rettig T, Bawa J, Sylverken J, Sambian D, Sarfo A, Agyekum A, Martinson F, Hoffman I, Mvalo T, Kamthunzi P, Nkomo R, Tembo T, Tegha G, Tsidya M, Kilembe J, Chawinga C, Ballou WR, Cohen J, Guerra Y, Jongert E, Lapierre D, Leach A, Lievens M, Ofori-Anyinam O, Olivier A, Vekemans J, Carter T, Kaslow D, Leboulleux D, Loucq C, Radford A, Savarese B, Schellenberg D, Sillman M, Vansadia P: A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N Engl J Med 2012, 367:2284–2295.PubMedView Article
                                            18. Asante KP, Abdulla S, Agnandji S, Lyimo J, Vekemans J, Soulanoudjingar S, Owusu R, Shomari M, Leach A, Jongert E, Salim N, Fernandes JF, Dosoo D, Chikawe M, Issifou S, Osei-Kwakye K, Lievens M, Paricek M, Moller T, Apanga S, Mwangoka G, Dubois MC, Madi T, Kwara E, Minja R, Hounkpatin AB, Boahen O, Kayan K, Adjei G, Chandramohan D, Carter T, Vansadia P, Sillman M, Savarese B, Loucq C, Lapierre D, Greenwood B, Cohen J, Kremsner P, Owusu-Agyei S, Tanner M, Lell B: Safety and efficacy of the RTS, S/AS01(E) candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis 2011, 11:741–749.PubMedView Article
                                            19. White MT, Griffin JT, Drakeley CJ, Ghani AC: Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials. Malar J 2010,9(82):1475–2875.
                                            20. Aide P, Aponte JJ, Renom M, Nhampossa T, Sacarlal J, Mandomando I, Bassat Q, Manaca MN, Leach A, Lievens M, Vekemans J, Dubois MC, Loucq C, Ballou WR, Cohen J, Alonso PL: Safety, immunogenicity and duration of protection of the RTS, S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial. PLoS One 2010, 5:e13838.PubMedView Article
                                            21. Aide P, Dobano C, Sacarlal J, Aponte JJ, Mandomando I, Guinovart C, Bassat Q, Renom M, Puyol L, Macete E, Herreros E, Leach A, Dubois MC, Demoitie MA, Lievens M, Vekemans J, Loucq C, Ballou WR, Cohen J, Alonso PL: Four year immunogenicity of the RTS, S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial. Vaccine 2011, 29:6059–6067.PubMedView Article
                                            22. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmuller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Nhamuave A, Quelhas D, Bassat Q, Mandjate S, Macete E, Alonso P, Abdulla S, Salim N, Juma O, Shomari M, Shubis K, Machera F, Hamad AS, Minja R, Mtoro A, Sykes A, Ahmed S, Urassa AM, Ali AM, Mwangoka G, Tanner M, Tinto H, D’Alessandro U, Sorgho H, Valea I, Tahita MC, Kabore W, Ouedraogo S, Sandrine Y, Guiguemde RT, Ouedraogo JB, Hamel MJ, Kariuki S, Odero C, Oneko M, Otieno K, Awino N, Omoto J, Williamson J, Muturi-Kioi V, Laserson KF, Slutsker L, Otieno W, Otieno L, Nekoye O, Gondi S, Otieno A, Ogutu B, Wasuna R, Owira V, Jones D, Onyango AA, Njuguna P, Chilengi R, Akoo P, Kerubo C, Gitaka J, Maingi C, Lang T, Olotu A, Tsofa B, Bejon P, Peshu N, Marsh K, Owusu-Agyei S, Asante KP, Osei-Kwakye K, Boahen O, Ayamba S, Kayan K, Owusu-Ofori R, Dosoo D, Asante I, Adjei G, Adjei G, Chandramohan D, Greenwood B, Lusingu J, Gesase S, Malabeja A, Abdul O, Kilavo H, Mahende C, Liheluka E, Lemnge M, Theander T, Drakeley C, Ansong D, Agbenyega T, Adjei S, Boateng HO, Rettig T, Bawa J, Sylverken J, Sambian D, Agyekum A, Owusu L, Martinson F, Hoffman I, Mvalo T, Kamthunzi P, Nkomo R, Msika A, Jumbe A, Chome N, Nyakuipa D, Chintedza J, Ballou WR, Bruls M, Cohen J, Guerra Y, Jongert E, Lapierre D, Leach A, Lievens M, Ofori-Anyinam O, Vekemans J, Carter T, Leboulleux D, Loucq C, Radford A, Savarese B, Schellenberg D, Sillman M, Vansadia P: First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011, 365:1863–1875.PubMedView Article
                                            23. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois MC, Lievens M, Cohen J, Ballou WR, Heppner DG Jr: Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009, 200:337–346.PubMedView Article

                                            Copyright

                                            © Abdulla et al.; licensee BioMed Central Ltd. 2013

                                            This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                                            Advertisement